|
|
Article: Fewer injections means more freedom for diabetics: Amylin's safe, innovative, and fully automated facility puts a once a week insulin injection in reach.(FACILITY PROFILE)(Company overview)
- Article from:
- Pharmaceutical Processing
- Article date:
- July 1, 2009
- Author:
CopyrightCOPYRIGHT 2009 Advantage Business Media. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
An estimated 246 million adults worldwide suffer from type 2 diabetes--a disease that inhibits the body's ability to produce or use insulin to properly regulate blood sugar levels. To supplement the body's inability to produce insulin, many diabetics rely on medical injections of insulin to manage their health condition. Unfortunately, for many diabetics this means taking multiple injections daily which involves a high level of personal responsibility and necessitates carrying around the equipment needed to administer their doses. Amylin Pharmaceuticals (a company based in San Diego, California) has developed BYETTA (exenatide) injections, which is an approved treatment ...